News
GLTO
0.7001
-2.36%
-0.0169
GLTO Stock Earnings: Galecto Beats EPS for Q1 2024
Galecto reported earnings per share of -20 cents for the first quarter of 2024. The company did not report any revenue for the quarter. Galecto's earnings were above the analyst estimate for EPS of -29 cents. The stock was down 1.7% after the report.
Investorplace · 1d ago
BRIEF-Galecto Announces First Patient Dosed In An Investigator-Initiated Phase 2 Trial Of Gb1211 In Combination With Pembrolizumab
Galecto Announces First Patient Dosed In An Investigator-Initiated Phase 2 Trial Of Gb1211 In Combination With Pembrolizumab. First Patient dosed in an investigator-initiated trial of GB1211 in combination with pembroliza.
Reuters · 3d ago
Galecto, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 5d ago
Weekly Report: what happened at GLTO last week (0422-0426)?
Weekly Report · 5d ago
Weekly Report: what happened at GLTO last week (0415-0419)?
Weekly Report · 04/22 09:04
Weekly Report: what happened at GLTO last week (0408-0412)?
Weekly Report · 04/15 09:04
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. Allarity Therapeutics stock rose 18.09% and Galecto stock increased by 5.58%. PaxMedica stock declined by 8.0% during the session.
Benzinga · 04/12 20:31
Weekly Report: what happened at GLTO last week (0401-0405)?
Weekly Report · 04/08 09:04
12 Health Care Stocks Moving In Monday's After-Market Session
OpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. Kyverna Therapeutics shares increased by 9.19%. Galecto and Ontrak also gained ground. Gritstone Bio and Aclarion were among the losers in the market.
Benzinga · 04/01 20:31
Weekly Report: what happened at GLTO last week (0325-0329)?
Weekly Report · 04/01 09:04
Weekly Report: what happened at GLTO last week (0318-0322)?
Weekly Report · 03/25 09:04
Weekly Report: what happened at GLTO last week (0311-0315)?
Weekly Report · 03/18 09:04
GLTO Stock Earnings: Galecto Beats EPS for Q4 2023
Galecto reported earnings per share of -22 cents. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -31 cents. Galecto is not listed as a company in the S&P 500 index of companies.
Investorplace · 03/15 17:53
12 Health Care Stocks Moving In Wednesday's After-Market Session
Molina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. Evoke Pharma (NASDAQ:EVOK) shares rose 18.54% and Aptorum Gr stock rose 11.75% during the session. Losers Spruce Biosciences and Bright Green stock declined by 75.2%.
Benzinga · 03/13 21:32
Weekly Report: what happened at GLTO last week (0304-0308)?
Weekly Report · 03/11 09:04
Weekly Report: what happened at GLTO last week (0226-0301)?
Weekly Report · 03/04 09:04
Weekly Report: what happened at GLTO last week (0219-0223)?
Weekly Report · 02/26 09:04
Weekly Report: what happened at GLTO last week (0212-0216)?
Weekly Report · 02/19 09:04
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
NASDAQ · 02/14 17:00
New Strong Buy Stocks for February 14th
NASDAQ · 02/14 10:48
More
Webull provides a variety of real-time GLTO stock news. You can receive the latest news about Galecto Inc. through multiple platforms. This information may help you make smarter investment decisions.
About GLTO
Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Company’s initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.